Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros

Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Int J Colorectal Dis ; 35(10): 1959-1962, 2020 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-32504330

RESUMEN

PURPOSE: No consensus exists regarding the use of preoperative bowel preparation for patients undergoing a low anterior resection (LAR). Several comparative studies show similar outcomes when a single time enema (STE) is compared with mechanical bowel preparation (MBP). It is hypothesized that STE is comparable with MBP due to a decrease in intestinal motility distal of a newly constructed diverting ileostomy (DI). METHODS: In this prospective single-centre cohort study, patients undergoing a LAR with primary anastomosis and DI construction were given a STE 2 h pre-operatively. Radio-opaque markers were inserted in the efferent loop of the DI during surgery, and plain abdominal X-rays were made during the first, third, fifth and seventh postoperative day to visualize intestinal motility. RESULTS: Thirty-nine patients were included. Radio-opaque markers were situated in the ileum or right colon in 100%, 100% and 97.1% of the patients during respectively the first, third and fifth postoperative day. One patient had its most distal marker situated in the left colon during day five. In none of the patients, the markers were seen distal of the anastomosis. CONCLUSION: Intestinal motility distally of the DI is decreased in patients who undergo a LAR resection with the construction of an anastomosis and DI, while preoperatively receiving a STE.


Asunto(s)
Ileostomía , Neoplasias del Recto , Anastomosis Quirúrgica , Estudios de Cohortes , Motilidad Gastrointestinal , Humanos , Complicaciones Posoperatorias , Estudios Prospectivos
3.
BMC Surg ; 15: 78, 2015 Jun 28.
Artículo en Inglés | MEDLINE | ID: mdl-26123286

RESUMEN

BACKGROUND: At least a third of patients with a colorectal carcinoma who are candidate for surgery, are anaemic preoperatively. Preoperative anaemia is associated with increased morbidity and mortality. In general practice, little attention is paid to these anaemic patients. Some will have oral iron prescribed others not. The waiting period prior to elective colorectal surgery could be used to optimize a patients' physiological status. The aim of this study is to determine the efficacy of preoperative intravenous iron supplementation in comparison with the standard preoperative oral supplementation in anaemic patients with colorectal cancer. METHODS/DESIGN: In this multicentre randomized controlled trial, patients with an M0-staged colorectal carcinoma who are scheduled for curative resection and with a proven iron deficiency anaemia are eligible for inclusion. Main exclusion criteria are palliative surgery, metastatic disease, neoadjuvant chemoradiotherapy (5 × 5 Gy = no exclusion) and the use of Recombinant Human Erythropoietin within three months before inclusion or a blood transfusion within a month before inclusion. Primary endpoint is the percentage of patients that achieve normalisation of the haemoglobin level between the start of the treatment and the day of admission for surgery. This study is a superiority trial, hypothesizing a greater proportion of patients achieving the primary endpoint in favour of iron infusion compared to oral supplementation. A total of 198 patients will be randomized to either ferric(III)carboxymaltose infusion in the intervention arm or ferrofumarate in the control arm. This study will be performed in ten centres nationwide and one centre in Ireland. DISCUSSION: This is the first randomized controlled trial to determine the efficacy of preoperative iron supplementation in exclusively anaemic patients with a colorectal carcinoma. Our trial hypotheses a more profound haemoglobin increase with intravenous iron which may contribute to a superior optimisation of the patient's condition and possibly a decrease in postoperative morbidity. TRIAL REGISTRATION: ClincalTrials.gov: NCT02243735 .


Asunto(s)
Anemia Ferropénica/tratamiento farmacológico , Neoplasias Colorrectales/cirugía , Compuestos Férricos/administración & dosificación , Compuestos Ferrosos/administración & dosificación , Fumaratos/administración & dosificación , Hematínicos/administración & dosificación , Maltosa/análogos & derivados , Cuidados Preoperatorios/métodos , Administración Oral , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Anemia Ferropénica/etiología , Protocolos Clínicos , Neoplasias Colorrectales/complicaciones , Suplementos Dietéticos , Femenino , Compuestos Férricos/uso terapéutico , Compuestos Ferrosos/uso terapéutico , Fumaratos/uso terapéutico , Hematínicos/uso terapéutico , Humanos , Infusiones Intravenosas , Masculino , Maltosa/administración & dosificación , Maltosa/uso terapéutico , Persona de Mediana Edad , Resultado del Tratamiento , Adulto Joven
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA